CBO-212 / Merck (MSD) - LARVOL DELTA

Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak Platform (GlobeNewswire) - "Cidara Therapeutics, Inc...announced that it has selected its first oncology drug-Fc conjugate (DFC) candidate from the company’s Cloudbreak^® platform: CBO-212, targeting CD73....'We look forward to advancing CBO-212 through IND enabling studies and providing updates on its progress in leading conferences as we continue to generate more data'."

New molecule • Oncology • Solid Tumor